OncoMatch/Clinical Trials/NCT07354711
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Is NCT07354711 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies 3H-10000 for lung cancer.
Treatment: 3H-10000 — The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Gastric Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational drug
Having received treatment with other investigational drugs within 4 weeks prior to the first dose of the study drug.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify